ATE457717T1 - LIQUIDS WITH SUSPENDED GLASS PARTICLES - Google Patents

LIQUIDS WITH SUSPENDED GLASS PARTICLES

Info

Publication number
ATE457717T1
ATE457717T1 AT05731023T AT05731023T ATE457717T1 AT E457717 T1 ATE457717 T1 AT E457717T1 AT 05731023 T AT05731023 T AT 05731023T AT 05731023 T AT05731023 T AT 05731023T AT E457717 T1 ATE457717 T1 AT E457717T1
Authority
AT
Austria
Prior art keywords
liquids
particles
glass particles
suspended
suspended glass
Prior art date
Application number
AT05731023T
Other languages
German (de)
Inventor
Bruce Joseph Roser
Original Assignee
Nova Bio Pharma Technologies L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nova Bio Pharma Technologies L filed Critical Nova Bio Pharma Technologies L
Priority claimed from PCT/GB2005/050050 external-priority patent/WO2005099669A1/en
Application granted granted Critical
Publication of ATE457717T1 publication Critical patent/ATE457717T1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Glass Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical composition comprising a biologically active agent preserved in particulate form, in particular a glass or amorphous particle, such as a sugar, a metal carboxylate, an amino acid or calcium phosphate, wherein said particles are suspended in at least one of a hydrofluoroether, a perfluoroether, a hydrofluoroamine, a perfluoroamine, a hydrofluorothioether, a perfluorothioether, a hydrofluoropolyether or a perfluoropolyether. The use of such fluorinated liquid media overcomes the problem of aggregation of particles and also is environmentally friendly.
AT05731023T 2004-04-13 2005-04-13 LIQUIDS WITH SUSPENDED GLASS PARTICLES ATE457717T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0408199.8A GB0408199D0 (en) 2004-04-13 2004-04-13 Liquids containing suspended sugar glass particles
GB0504501A GB2413075B (en) 2004-04-13 2005-03-07 Liquids containing suspended glass particles
PCT/GB2005/050050 WO2005099669A1 (en) 2004-04-13 2005-04-13 Liquids containing suspended glass particles

Publications (1)

Publication Number Publication Date
ATE457717T1 true ATE457717T1 (en) 2010-03-15

Family

ID=32320732

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05731023T ATE457717T1 (en) 2004-04-13 2005-04-13 LIQUIDS WITH SUSPENDED GLASS PARTICLES

Country Status (10)

Country Link
CN (1) CN1942171B (en)
AT (1) ATE457717T1 (en)
DE (1) DE602005019398D1 (en)
DK (1) DK1750668T3 (en)
ES (1) ES2339783T3 (en)
GB (2) GB0408199D0 (en)
MX (1) MXPA06011895A (en)
PT (1) PT1750668E (en)
RU (1) RU2363447C2 (en)
ZA (1) ZA200609158B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0517688D0 (en) * 2005-08-31 2005-10-05 Cambridge Biostability Ltd Improvements in the stabilisation of biological materials
GB0523638D0 (en) 2005-11-21 2005-12-28 Cambridge Biostability Ltd Pharmaceutical device for the administration of substances to patients
US9243626B2 (en) 2012-11-19 2016-01-26 Nordson Corporation Adhesive dispensing system and method including a pump with integrated diagnostics

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07258027A (en) * 1994-03-16 1995-10-09 Shiseido Co Ltd Makeup cosmetic
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6190701B1 (en) * 1999-03-17 2001-02-20 Peter M. Ronai Composition and method for stable injectable liquids
AU2046101A (en) * 1999-11-22 2001-06-04 Universal Preservation Technologies, Inc. Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
KR20030096224A (en) * 2000-10-13 2003-12-24 캠브리지 바이오스테빌리티 리미티드 Composition and method for stable injectable liquids

Also Published As

Publication number Publication date
ES2339783T3 (en) 2010-05-25
GB2413075A (en) 2005-10-19
DK1750668T3 (en) 2010-05-10
DE602005019398D1 (en) 2010-04-01
GB0408199D0 (en) 2004-05-19
MXPA06011895A (en) 2007-11-20
GB2413075B (en) 2009-01-21
CN1942171B (en) 2011-04-06
PT1750668E (en) 2010-04-07
ZA200609158B (en) 2008-06-25
GB0504501D0 (en) 2005-04-13
RU2006137275A (en) 2008-05-20
RU2363447C2 (en) 2009-08-10
CN1942171A (en) 2007-04-04

Similar Documents

Publication Publication Date Title
Kim et al. Synthesis and characterization of injectable poly (N-isopropylacrylamide-co-acrylic acid) hydrogels with proteolytically degradable cross-links
DE502005009045D1 (en) MAGNETORHEOLOGICAL MATERIALS WITH HIGH SWITCHING FACTOR AND ITS USE
CO5660273A2 (en) PROTEIN AND HIGH CONCENTRATION ANTIBODY FORMULATIONS
DE502004007577D1 (en) Lymerpartikel
DE602005015229D1 (en) MEDICAL ARTICLES MADE OF MIXED POLYMER PARTICLES IN MEANS OF ACTIVE SUBSTANCES
HK1135609A1 (en) Formation of medically useful gels comprising microporous particles and methods of use
EA200802140A1 (en) LIQUID COMPOSITION CONTAINING THE ASPARAGIN PROTEAS
FR2881648B1 (en) COSMETIC COMPOSITION COMPRISING A POLYMER PARTICLE DISPERSION, POLYMER PARTICLE DISPERSION AND COSMETIC PROCESS USING THE SAME
GB2464038A (en) System, method, and apparatus for combined fracturing treatment and scale inhibition
EA200701884A1 (en) FOOD LIPID COMPOSITION IN THE FORM OF PARTICLES
EP2335575A3 (en) Magnetic gas bubble composition and magnetic gas bubble precursor for its manufacture
WO2007111681A3 (en) Device and methods for liquid crystal-based bioagent detection
ATE529499T1 (en) GRANULES OF A SENSITIVE DETERGENT OR CLEANING INGREDIENT
EP4218718A3 (en) Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
FR2856692A1 (en) PROCESS FOR THE PREPARATION OF POLYAMIDE-BASED SPHERICAL PARTICLES.
WO2007082155A3 (en) Molecules with complexing groups for aqueous nanoparticle dispersions and uses thereof
ATE457717T1 (en) LIQUIDS WITH SUSPENDED GLASS PARTICLES
PL2397510T3 (en) High concentration pelletized additive concentrates for polymer
DE60234945D1 (en) POWDER FOR NASAL ADMINISTRATION OF ACTIVE SUBSTANCES
ATE527002T1 (en) SUPPORT MATERIAL FOR A MEDICAL IMPLANT
DE602007005146D1 (en) AMMENSETZUNG
TR200102988T2 (en) Absorbents for use in handling complex liquids.
Peng et al. The surface characteristics of chitosan modified PSt-GMA microspheres influenced the interactions and properties of immobilized pepsin
FR2890449B1 (en) METHOD FOR MANAGING LOCATIONS OF UNITS, IN PARTICULAR NAVIGATING UNITS AND ASSOCIATED DEVICE
ITMI20061545A1 (en) PARTICLES ABLE TO RELEASE THE ACTIVE PRINCIPLE FOR A PROLONGED PERIOD OF TIME

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties